Immunitas Therapeutics
Cambridge
About Immunitas Therapeutics
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors. At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $97.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2021)
- Website: immunitastx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunitas-therapeutics-55306 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.